Jason Pitts
Principal General Atlantic
Seminars
Wednesday 16th September 2026
Panel Discussion: Future Directions & Strategic Investment to Fuel the Next Wave of Neuropsychiatric Therapeutics
4:30 pm
- How has investor sentiment evolved as neuropsychiatry moves from scientific validation toward commercial execution and scalability?
- What constitutes an attractive opportunity in today's investment landscape?
- How are investors evaluating next-generation psychedelic approaches, including non-hallucinogenic neuroplastogens and differentiated product profiles?
- Which emerging therapeutic areas and indications are generating the greatest excitement across neuropsychiatry?
- What scientific, clinical and commercial milestones are investors looking for before committing capital?
